

BSW Formulary Update – February 2022

New and Updated Shared Care Agreements (SCAs) and Prescribing Guidance

- [The pharmacological management of overactive bladder disease in adults](#) – **updated** to include MR preparations of tolterodine and trospium.
- [Primary Care Guideline for inclisiran](#) – **updated** to include new costings for secondary care and additional information on black triangle status.
- [BSW HRT Formulary Treatment Options](#) – **updated** to reflect recent discussions and changes to formulary choices.
- [Biologic treatment pathway for mod-sev Plaque Psoriasis in Adults](#) – **updated** to include bimekizumab in line with [NICE TA723](#)
- **BSW SCAs** for using Epistatus® brand of buccal midazolam replace previous locality SCAs: [BSW Epistatus® \(Oromucosal Buccal Midazolam\) for children <10 years of age \(unlic use\)](#) [BSW Epistatus® \(Oromucosal Buccal Midazolam\) for children ≥10 years of age](#)

We remind prescribers that since Nov 2021:

- **Buccolam® is first choice brand when new patients require oromucosal midazolam for emergency treatment of status epilepticus.** [BSW Buccolam SCA](#)
- Buccolam® is licensed for use in children from 3 months to < 18 years.
- The Epistatus® brand of oromucosal midazolam is only licensed to be used in children from age 10 to <18 years and should only be initiated in new patients, or continued in existing patients, where there is a compelling reason to use this more concentrated solution. Specialist nurses are reviewing existing cohort of patients using Epistatus® with the aim to switch them to Buccolam®.
- Buccolam® and Epistatus® are NOT interchangeable; **prescribe by brand name.**
- All patients should be prescribed the pre-filled syringes which are designed to deliver the dose required i.e. **do not prescribe part doses of a prefilled syringe and do not prescribe multi-dose bottles** due to the safety risk of drawing up the wrong dose.

New additions to BSWformulary

- [Co-enzyme Q10 \(ubidecarenone/ubiquinone\) 30mg and 100mg oral capsules](#) – added with **AMBER SCA** TLS only for use in the (off-label) treatment of mitochondrial disorders in children. Use for this indication may then continue lifelong. SCA for this indication [here](#).
- Xarelto® [rivaroxaban 1mg/ml granules for suspension](#). Added for the treatment of VTE and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged <18 years after at least 5 days of initial parenteral anticoagulation treatment. **AMBER TLS**. Note that rivaroxaban granules for suspension are not licensed nor included on our formulary for use in adults. For information on appropriate choice of oral anticoagulants in adults unable to swallow solid dose forms, see SPS resource [here](#)
- [Nirmatrelvir \(PF-07321132\) and Ritonavir tablets \(Paxlovid®\)](#) added with **RED TLS** for use only in line with NHS commissioning policy and according to Trust procedures

Other BSWformulary website updates

- [Ciprofloxacin 0.3%/Dexamethasone 0.1% eardrops 5ml](#) added with **GREEN TLS** and [Ciprofloxacin 2mg/ml single unit dose eardrops](#) aligned with **AMBER TLS**. The suggestion to use ciprofloxacin or ofloxacin **eyedrops** in the ear (unlicensed use) has been removed.
- Diprobace® ointment and Diprobace® cream removed from formulary; ointment discontinued and cream has been reformulated. Existing patients can be switched to alternative formulary product see [here](#) or directed to self-purchase.
- As part of ongoing work to build the 'devices' chapter of our formulary, we have included information on approved indications for the restricted prescribing of **waterproof protectors** e.g. **LimbO/SealTight** on FP10 [here](#). These protectors are available OTC and online; in most instances, patients should be directed to self-purchase.
- A **non-formulary** entry has been created for coenzyme Q10 supplements in adults as a reminder that there is insufficient evidence to recommend their use for example in statin-induced muscle symptoms. These supplements should be self-purchased OTC. SPS has further information on this indication [here](#)

Some of the things the BSW CCG formulary team are currently working on

- Working with the BSWCCG Medicines Optimisation Team to review Optimise Profiles in line with BSWformulary. *Please contact bswccg.prescribing@nhs.net in the first instance to clarify TLS status if you have prescribing queries.*
- Reviewing the drugs on BSWformulary that are currently assigned an **AMBER TLS** and where there is no formal SCA in place.
- Reviewing the national SCA consultations by [RMOC](#).
- Reviewing our BSW melatonin guidance.
- Working with the local diabetes teams to produce BSW Type 2 diabetes treatment guidance and to produce a BSW insulin formulary.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net